Viatris News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.03.22	Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partner... (PR Newswire)
16.03.22	FDA Approves First Generic Of Symbicort To Treat Asthma, COPD (RTTNews)
01.03.22	Viatris to Participate in Upcoming Investor Conferences (PR Newswire)
28.02.22	Biocon Biologics To Buy Viatris' Biosimilars Assets For Up To $3.335 Bln In Stock, Cash (RTTNews)
28.02.22	Viatris Inc. Q4 Loss Decreases (RTTNews)
28.02.22	Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Fu... (PR Newswire)
04.02.22	Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 (PR Newswire)
04.02.22	Viatris Receives FDA Approval For Generic Restasis To Treat Dry Eye Disease (RTTNews)
03.02.22	Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease (PR Newswire)
20.01.22	Mylan Recalls Certain Semglee(insulin Glargine) Prefilled Pens (RTTNews)
06.01.22	Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend (PR Newswire)
30.12.21	Viatris Wins Court Decisions On Sanofi Appeals Of Lantus Patent Invalidations (RTTNews)
30.12.21	Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations (PR Newswire)
17.12.21	Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results (PR Newswire)
06.12.21	Viatris Named by Newsweek as One of America's Most Responsible Companies (PR Newswire)
01.12.21	Viatris Wins Federal Circuit Court Appeal On Biogen's Tecfidera Patent - Quick Facts (RTTNews)
01.12.21	Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent (PR Newswire)
18.11.21	Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference (PR Newswire)
16.11.21	Viatris, Biocon Launch Biosimilar Products Interchangeable For LANTUS - Quick Facts (RTTNews)
16.11.21	Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection (PR Newswire)
11.11.21	Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities (PR Newswire)
08.11.21	Viatris Inc. Q3 sales increase (RTTNews)
08.11.21	Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022 (PR Newswire)
20.10.21	Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary (PR Newswire)
11.10.21	Viatris Named Fifth on Fortune's Change the World List (PR Newswire)
09.08.21	Viatris Boosts FY21 Revenue Outlook, Declares Dividend - Quick Facts (RTTNews)
09.08.21	EARNINGS SUMMARY: Details of Viatris Inc. Q2 Earnings Report (RTTNews)
09.08.21	Viatris Reports Strong Second Quarter Results (PR Newswire)
29.07.21	Viatris Gets FDA Approval For Interchangeable Biosimilar Semglee For Diabetes Treatment (RTTNews)
29.07.21	Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes (PR Newswire)
27.07.21	Viatris : Mylan Wins Dismissal Of Kansas EpiPen Direct Purchaser Case (RTTNews)
08.07.21	Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021 (PR Newswire)
24.06.21	Mylan Wins Summary Judgment Rulings In Kansas EpiPen Auto-Injector Class Action (RTTNews)
10.05.21	Viatris Reaffirms FY21 Revenue Outlook, Declares Dividend - Quick Facts (RTTNews)
10.05.21	EARNINGS SUMMARY: Details of Viatris Inc. Q1 Earnings Report (RTTNews)
08.03.21	Viatris : FDA Grants Tentative Approval Of Budesonide/formoterol Fumarate Dihydrate Products (RTTNews)
22.02.21	Viatris Sees FY21 Revenue Below View - Quick Facts (RTTNews)
11.12.20	Viatris Says Restructuring To Impact 15 Manufacturing Facilities, Up To 20% Of Workforce (RTTNews)
30.11.20	Biotech Stocks Facing FDA Decision In December 2020 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

24.12.24		Aufschläge in New York: S&P 500 verbucht zum Handelsende Zuschläge
24.12.24		Optimismus in New York: So entwickelt sich der S&P 500 am Nachmittag
09.12.24		S&P 500-Titel Viatris-Aktie: So hoch ist die Dividende von Viatris
07.11.24		Pluszeichen in New York: S&P 500 zum Handelsende auf grünem Terrain
07.11.24		Börse New York in Grün: Am Donnerstagnachmittag Gewinne im S&P 500
07.11.24		S&P 500 aktuell: S&P 500 präsentiert sich am Mittag fester
07.11.24		Gute Stimmung in New York: S&P 500 zum Handelsstart im Aufwind
20.09.24		Schwacher Handel in New York: S&P 500 verbucht schlussendlich Verluste

24.12.24

Aufschläge in New York: S&P 500 verbucht zum Handelsende Zuschläge

24.12.24

Optimismus in New York: So entwickelt sich der S&P 500 am Nachmittag

09.12.24

S&P 500-Titel Viatris-Aktie: So hoch ist die Dividende von Viatris

07.11.24

Pluszeichen in New York: S&P 500 zum Handelsende auf grünem Terrain

07.11.24

Börse New York in Grün: Am Donnerstagnachmittag Gewinne im S&P 500

07.11.24

S&P 500 aktuell: S&P 500 präsentiert sich am Mittag fester

07.11.24

Gute Stimmung in New York: S&P 500 zum Handelsstart im Aufwind

20.09.24

Schwacher Handel in New York: S&P 500 verbucht schlussendlich Verluste

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Viatris Inc Registered Shs

Aktien Top/Flop

Viatris Peer Group Nachrichten

Meistgelesene Nachrichten